Neoplasms: Liver (hepatic hemangiosarcoma, liver cell adenoma, hepatocellular carcinoma ); breast (fibrocystic disease, breast carcinoma); endometrium (endometrial carcinoma); nervous system ( astrocytoma , pituitary tumor, prolactinoma, neurofibromatosis , glioblastoma multiforme , brain abcess); ovary (luteoma of pregnancy, dermoid cyst of the ovary , ovarian carcinoma); trophoblastic (hydatiform mole, choriocarcinoma ); miscellaneous ( melanoma , myeloma , perianal cysts, renal cell carcinoma , Hodgkin's lymphoma, tongue carcinoma, bladder carcinoma)
Due to its effects on gastric acid secretion, esomeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole. Esomeprazole is an enantiomer of omeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects). Co-administration of digoxin with NEXIUM is expected to increase the systemic exposure of digoxin. Therefore, patients may need to be monitored when digoxin is taken concomitantly with NEXIUM.